TY - JOUR
T1 - Side effects of CoronaVac® COVID-19 vaccination: Investigation in North Jakarta district public health center communities in Indonesia
AU - Ramatillah, Diana Laila
AU - Gan, Siew Hua
AU - Novarticia, Judith
AU - Araminda, Gena Nafta
AU - Michael, Michael
AU - Elnaem, Mohammad
AU - Alawuddin, Rizki
AU - Khan, Kashifullah
N1 - Publisher Copyright:
© 2024 The Author(s)
PY - 2024/4/26
Y1 - 2024/4/26
N2 - BackgroundThe decreasing prevalence of COVID-19 has highlighted the value of vaccinations. CoronaVac® vaccine was one of the most widely used vaccines in Indonesia, in other Southeast Asian countries, as well as in Latin America. However, to date the safety and side effect profiles of CoronaVac® vaccine among the Indonesian population have not been reported.ObjectiveIn this study, the CoronaVac® safety profiles were determined in a community of a public health center in North Jakarta, Indonesia.MethodThis is a descriptive cross-sectional questionnaire-based study on vaccine side effects as recorded in the yellow form (MESO). Patients (n = 300) who received CoronaVac® vaccinations between July and August 2021 were enrolled. SPSS was used to analyze the descriptive data.ResultsMost respondents were women (72.7 %) between the ages of 17 and 21 years. A significantly (p = 0.009) positive correlation was established between the vaccine side effects (namely pain at the injection site) with the female gender. Other side effects such as fatigue (p = 0.034) and headache (p ConclusionOverall, the side effects following the first and the second doses were generally mild and included fever, pain in the injection area, fatigue, headache, drowsiness, diarrhea, cough, and nausea. Regarding vaccine efficacy, CoronaVac® confers better protection following the second dose administration where the percentage of respondents affected with COVID-19 (26.7 %) decreased to only 20.3 % following the second dose.
AB - BackgroundThe decreasing prevalence of COVID-19 has highlighted the value of vaccinations. CoronaVac® vaccine was one of the most widely used vaccines in Indonesia, in other Southeast Asian countries, as well as in Latin America. However, to date the safety and side effect profiles of CoronaVac® vaccine among the Indonesian population have not been reported.ObjectiveIn this study, the CoronaVac® safety profiles were determined in a community of a public health center in North Jakarta, Indonesia.MethodThis is a descriptive cross-sectional questionnaire-based study on vaccine side effects as recorded in the yellow form (MESO). Patients (n = 300) who received CoronaVac® vaccinations between July and August 2021 were enrolled. SPSS was used to analyze the descriptive data.ResultsMost respondents were women (72.7 %) between the ages of 17 and 21 years. A significantly (p = 0.009) positive correlation was established between the vaccine side effects (namely pain at the injection site) with the female gender. Other side effects such as fatigue (p = 0.034) and headache (p ConclusionOverall, the side effects following the first and the second doses were generally mild and included fever, pain in the injection area, fatigue, headache, drowsiness, diarrhea, cough, and nausea. Regarding vaccine efficacy, CoronaVac® confers better protection following the second dose administration where the percentage of respondents affected with COVID-19 (26.7 %) decreased to only 20.3 % following the second dose.
KW - Vaccine
KW - Side effects
KW - COVID-19
KW - CoronaVac vaccine
KW - AEFI
KW - CoronaVac® vaccine
UR - http://www.scopus.com/inward/record.url?scp=85191544727&partnerID=8YFLogxK
UR - https://pure.ulster.ac.uk/en/publications/dee72023-9735-46cf-a763-9d39593c29f0
U2 - 10.1016/j.heliyon.2024.e30087
DO - 10.1016/j.heliyon.2024.e30087
M3 - Article
C2 - 38694099
SN - 2405-8440
VL - 10
SP - 1
EP - 12
JO - Heliyon
JF - Heliyon
IS - 9
M1 - e30087
ER -